Skip to main content
. Author manuscript; available in PMC: 2022 Feb 18.
Published in final edited form as: Mol Cancer Ther. 2020 May 19;19(8):1708–1718. doi: 10.1158/1535-7163.MCT-20-0015

Figure 5. Targeting AKR1C3 resensitizes apalutamide resistant cells to apalutamide and enzalutamide.

Figure 5.

A. C4-2B APALR cells were treated with 20 µM enzalutamide, 20 µM apalutamide or infected with lenti-AKR1C3 shRNA, alone or in combination. Total cell numbers were determined on 3 and 5 days. B. C4-2B APALR cells were infected with lenti-control shRNA or lenti-AKR1C3 shRNA and then treated with 20 µM enzalutamide or 20 µM apalutamide. After 5 days, whole cell lysates were collected and subjected to western blot. C. C4-2B APALR cells treated with 0, 20, 40 µM indomethacin with or without 20 μM apalutamide and cell numbers were determined after 5 days. D-E. The clonogenic ability of C4-2B ARNR cells treated with 0, 20, 40 µM indomethacin with or without 20 μM apalutamide was analyzed. APAL: apalutamide, ENZA: enzalutamide. INDO: indomethacin * p<0.05.